Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-CA-21-052

Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)

Closed on November 1, 2021.

Posted
August 3, 2021
Close date
November 1, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
5
3 new, 2 renewals
Median first-year cost
$1,284,334
$6,306,724 in all
Institutions
4
5 contact PIs
Patents
2
from 1 funded project

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. UNIVERSITY OF TX MD ANDERSON CAN CTR2
  2. OREGON HEALTH & SCIENCE UNIVERSITY1
  3. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
  4. UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR1

Most frequent study sections

  1. Special Emphasis Panel (ZCA1 SRB-E (M1))5
5 awards under RFA-CA-21-052 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2022Acquired Resistance to Therapy and Iron (ARTI) Center1U54CA274220-01Gan, BoyiKoong, AlbertUNIVERSITY OF TX MD ANDERSON CAN CTR, TXFirst-year cost $1,356,890Study section ZCA1
FY2022Architecture and Trajectory of Acquired Resistance to Therapy in AML2U54CA224019-05Druker, Brian JMcWeeney, Shannon K.Tyner, Jeffrey WallaceOREGON HEALTH & SCIENCE UNIVERSITY, ORFirst-year cost $1,308,998Study section ZCA1
FY2022Pancreatic Cancer ARTNet Center1U54CA274329-01Singh, Pankaj KumarUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OKFirst-year cost $1,284,334Study section ZCA1
FY2022The Houston Center for Acquired Resistance Research (H-CARR)1U54CA274321-01Myers, Jeffrey NicholasSandulache, Vlad CUNIVERSITY OF TX MD ANDERSON CAN CTR, TXFirst-year cost $1,237,322Study section ZCA1
FY2022BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)2U54CA224081-05Bivona, Trever GRoth, JackUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CAFirst-year cost $1,119,180Study section ZCA1
Newest fiscal year first, then first-year cost.

Patents from its funded projects

2 patents name 1 of the 5 funded projects.

  1. US 12,472,175 (opens the patent at USPTO, a PDF, in a new tab)METHODS OF TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIAGranted November 18, 2025 to Oregon Health & Science UniversityU54CA224019 · OREGON HEALTH & SCIENCE UNIVERSITY, OR
  2. US 11,162,547 (opens the patent at USPTO, a PDF, in a new tab)CLUTCH-BY-WIRE SYSTEMGranted November 2, 2021 to HONDA MOTOR CO., LTD.U54CA224019 · OREGON HEALTH & SCIENCE UNIVERSITY, OR

Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.

Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-16-0.3.5. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-CA-21-052: Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed) | ConductScience ScienceDex